Navigation Links
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

s. In July, Memory Pharmaceuticals presented preclinical data for MEM 68626, its lead 5-HT6 antagonist, in a poster presentation at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease. The results demonstrate that MEM 68626 is effective in models of cognition that are considered predictive of efficacy in Alzheimer's disease and mild cognitive impairment.

The Company also reported that six abstracts related to the Company's clinical and preclinical programs have been accepted for poster presentations at the 38th Annual Meeting of the Society for Neuroscience in Washington, D.C. from November 15 - 19, 2008. The abstracts include additional preclinical data for R3487/MEM 3454, new preclinical data for MEM 68626 and data from its collaboration with Amgen focused on the development of PDE10 inhibitors.

-- Raised $2.0 Million under SMRI Equity Financing Agreement. In August, Memory Pharmaceuticals raised $2.0 million in the third and final tranche of its June 2007 equity financing agreement with an investment group led by The Stanley Medical Research Institute (SMRI).

-- Realigned Workforce to Support Development Programs. In September, the Company implemented a reduction in its workforce designed to reduce its costs and direct its resources toward its clinical programs. The cost reductions associated with the eliminated positions will help the Company to continue to execute its development strategy and support its key programs, including the ongoing and expected trials for its clinical-stage drug candidates.

-- Transferred to the NASDAQ Capital Market and Granted Extension to Comply with NASDAQ Listing Requirements. In October, the NASDAQ Listing Qualifications Panel transferred the listing for the Company's common stock from The NASDAQ Global Market to The NASDAQ Capital Market and granted the Company until December 3, 2008 to comply with the NASDAQ Capital Market minimum market capitalization requirement of $35 m
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Miniaturizing memory: Taking data storage to the molecular level
2. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Memoirs of a qubit: Hybrid memory solves key problem for quantum computing
6. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
7. Jellyfish Protein Shows Potential to Help With Memory
8. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
10. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
11. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Mass., Nov. 9, 2010 Boston Scientific Corporation (NYSE: ... of its Vercise™ Deep Brain Stimulation (DBS) System as ... multi-center, prospective trial designed to examine the improvement of ... the Vercise DBS System for the treatment of Parkinson,s ...
... novel, real-time imaging system, scientists have tracked a group ... lungs, into the body and out again, providing a ... particles which could be used in developing therapeutic agents ... greater understanding of the health effects of air pollution. ...
... (Nasdaq: KNDL ), a leading, global full-service ... the third quarter of 2010 of $131.4 million. Contract ... to $10.4 million or 1.3 percent of the Company,s ... book-to-bill of 1.5. New business authorizations (backlog) at Sept. ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Kendle Announces Third Quarter 2010 Results 2Kendle Announces Third Quarter 2010 Results 3Kendle Announces Third Quarter 2010 Results 4Kendle Announces Third Quarter 2010 Results 5Kendle Announces Third Quarter 2010 Results 6
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/2/2015)... March 2, 2015 Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new implementation ... to enable rapid and secure transactions and reliable ... gaming is a turnkey solution providing mouse and ... quickly integrate fingerprint ID solutions into their product ...
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial Services ... in the Health and Fitness Industry, today announced ... to MYiCLUBonline.  The latest upgrade includes advances to ... of cardless check-in via Identity One fingerprint biometrics. ... time through interactive displays at the International Health, ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... 2011 Based on its recent analysis of ... recognizes Cardiocom with the 2011 North American Frost ... integrated clinical telehealth services that offer significant cost ...   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) Cardiocom combines advanced ...
... Inexpensive igloo-shaped, pollution-eating devices nicknamed "Poo-Gloos" can ... treatment facilities for towns outgrowing their waste-treatment lagoons, ... results of this study show that it is ... hundreds of thousands, if not millions of dollars, ...
... rethinking what happens on the surface of things, engineers ... biofilm colonies exhibit an unmatched ability to repel ... across yet only hundreds of microns thick, such slimy ... pipes to teeth and are notoriously resistant to antimicrobial ...
Cached Biology News:Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Igloo-shaped 'Poo-Gloos' eat sewage 2Igloo-shaped 'Poo-Gloos' eat sewage 3Igloo-shaped 'Poo-Gloos' eat sewage 4Igloo-shaped 'Poo-Gloos' eat sewage 5A pesky bacterial slime reveals its survival secrets 2A pesky bacterial slime reveals its survival secrets 3
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... Tecan has 20 years of expertise ... (ELISA), and still offers the most powerful ... manages up to 40 000 in-microplate tests ... The integration of different modules (such as ...
... 6 delivers enhanced statistics and statistical ... quality improvement managers. As an accepted ... 6 simplifies statistics for novice users ... by experts. It offers a powerful ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Biology Products: